1. Ablasser A et al. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol. 2009 Jun 1;182(11):6824-33.

2. Abrams MT et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther. 2010 Jan;18(1):171-80.

3. Abul-Hassan K et al. Optimization of non-viral gene transfer to human primary retinal pigment epithelial cells. Curr Eye Res. 2000 May;20(5):361-6.

4. Akashi H et al. Escape from the interferon response associated with RNA interference using vectors that encode long modified hairpin-RNA Mol Biosyst. 2005 Dec;1(5-6):382-90.

5. Akita H, Kogure K, Moriguchi R, Nakamura Y, Higashi T, Nakamura T, Serada S, Fujimoto M, Naka T, Futaki S, Harashima H. Reprint of: Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. J Control Release. 2011 Jan 5;149(1):58-64.

6. Alshamsan A et al. Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine. Mol Pharm. 2009 Jan-Feb;6(1):121-33.

7. Alvarez R et al. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother. 2009 Sep;53(9):3952-62.

8. Andaloussi SE, Lehto T, Mäger I, Rosenthal-Aizman K, Oprea II, Simonson OE, Sork H, Ezzat K, Copolovici DM, Kurrikoff K, Viola JR, Zaghloul EM, Sillard R,Johansson HJ, Said Hassane F, Guterstam P, Suhorutšenko J, Moreno PM, Oskolkov N, Hälldin J, Tedebark U, Metspalu A, Lebleu B, Lehtiö J, Smith CI,Langel U.Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res. 2011 May;39(9):3972-87.

9. Andersen MØ et al. Delivery of siRNA from lyophilized polymeric surfaces. Biomaterials. 2008 Feb;29(4):506-12. Epub 2007 Oct 24.

10. Anderson DG et al. A polymer library approach to suicide gene therapy for cancer. Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16028-33.

11. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, Ostroff GR, Czech MP. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature. 2009 Apr 30;458(7242):1180-4.

12. Armstrong ME, Gantier M, Li L, Chung WY, McCann A, Baugh JA, Donnelly SC. Small interfering RNAs induce macrophage migration inhibitory factor production and proliferation in breast cancer cells via a double-stranded RNA-dependent protein kinase-dependent mechanism. J Immunol. 2008 Jun 1;180(11):7125-33.

13. Arnold AS et al. Comparing reagents for efficient transfection of human primary myoblasts: FuGENE 6, Effectene and ExGen 500. Fundam Clin Pharmacol. 2006 Feb;20(1):81-9.

14. Awasthi S, Cox RA. Transfection of murine dendritic cell line (JAWS II) by a nonviral transfection reagent. Biotechniques. 2003 Sep;35(3):600-2, 604.

15. Basha G, Novobrantseva TI, Rosin N, Tam YY, Hafez IM, Wong MK, Sugo T, Ruda VM, Qin J, Klebanov B, Ciufolini M, Akinc A, Tam YK, Hope MJ, Cullis PR. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther. 2011 Dec;19(12):2186-200. doi: 10.1038/mt.2011.190.

16. Bauer M et al. Prevention of interferon-stimulated gene expression using microRNA-designed hairpins. Gene Ther. 2009 Jan;16(1):142-7.

17. Baum P et al. Off-target analysis of control siRNA molecules reveals important differences in the cytokine profile and inflammation response of human fibroblasts. Oligonucleotides. 2010 Feb;20(1):17-26.

18. Beyerle A et al. Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice. J Control Release. 2011 Jan 9.

19. Beyerle A et al. In vitro cytotoxic and immunomodulatory profiling of low molecular weight polyethylenimines for pulmonary application. Toxicol In Vitro. 2009 Apr;23(3):500-8.

20. Bitko V et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med. 2005 Jan;11(1):50-5. Epub 2004 Dec 26.

21. Bøe S et al. Photochemically induced gene silencing using small interfering RNA molecules in combination with lipid carriers. Oligonucleotides. 2007;17(2):166-73.

22. Bolcato-Bellemin AL et al. Sticky overhangs enhance siRNA-mediated gene silencing. Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16050-5.

23. Bonnet ME et al. Systemic Delivery of DNA or siRNA Mediated by Linear Polyethylenimine (L-PEI) Does Not Induce an Inflammatory Response. Pharm Res. 2008 Dec;25(12):2972-82.

24. Bourquin C et al. Delivery of Immunostimulatory RNA Oligonucleotides by Gelatin Nanoparticles Triggers an Efficient Antitumoral Response. J Immunother. 2010 Nov-Dec;33(9):935-44.

25. Bramsen JB et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 2009. May;37(9):2867-81.

26. Bramsen JB et al. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res. 2007;35(17):5886-97.

27. Bridge AJ et al. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet. 2003 Jul;34(3):263-4.

28. Cao W et al. DNA constructs designed to produce short hairpin, interfering RNAs in transgenic mice sometimes show early lethality and an interferon response. J Appl Genet. 2005;46(2):217-25.

29. Carmona S et al. Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther. 2006 Feb;13(2):411-21.

30. Ceballos C et al. Cationic nucleoside lipids based on a 3-nitropyrrole universal base for siRNA delivery. Bioconjug Chem. 2009 Feb;20(2):193-6.

31. Cekaite L et al. Gene expression analysis in blood cells in response to unmodified and 2'-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol. 2007 Jan 5;365(1):90-108. Epub 2006 Sep 16.

32. Chang C et al. Dual-target gene silencing by using long, synthetic siRNA duplexes without triggering antiviral responses. Mol Cells. 2009 Jun 30;27(6):689-95.

33. Chattopadhyay S et al. Inhibition of hepatitis B virus replication with linear DNA sequences expressing antiviral micro-RNA shuttles. Biochem Biophys Res Commun. 2009 Nov 20;389(3):484-9.

34. Cho WG, Albuquerque RJ, Kleinman ME, Tarallo V, Greco A, Nozaki M, Green MG, Baffi JZ, Ambati BK, De Falco M, Alexander JS, Brunetti A, De Falco S, Ambati J. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7137-42.

35. Clements BA et al. A comparative evaluation of poly-L-lysine-palmitic acid and Lipofectamine 2000 for plasmid delivery to bone marrow stromal cells. Biomaterials. 2007 Nov;28(31):4693-704.

36. Collingwood MA et al. Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides. 2008 Jun;18(2):187-200.

37. Dalby B et al. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Mol Biotechnol. 2004 Jun;33(2):95-103.

38. Dang LT et al. Engineered virus-encoded pre-microRNA (pre-miRNA) induces sequence-specific antiviral response in addition to nonspecific immunity in a fish cell line: convergence of RNAi-related pathways and IFN-related pathways in antiviral response. Antiviral Res. 2008 Dec;80(3):316-23.

39. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO 2nd, Giangrande PH.Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol. 2009 Sep;27(9):839-49.

40. Deleavey GF et al. Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing. Nucleic Acids Res. 2010 Jul;38(13):4547-57.

41. Dickens S et al. Nonviral transfection strategies for keratinocytes, fibroblasts, and endothelial progenitor cells for ex vivo gene transfer to skin wounds. Tissue Eng Part C Methods. 2010 Dec;16(6):1601-8.

42. Diebold SS et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004 Mar 5;303(5663):1529-31. Epub 2004 Feb 19.

43. Djurovic S et al. Comparison of nonviral transfection and adeno-associated viral transduction on cardiomyocytes. Mol Biotechnol. 2004 Sep;28(1):21-32.

44. Ebadi P et al. The efficiency of CD40 down regulation by siRNA and antisense ODN: comparison of lipofectamine and FuGENE6. Iran J Immunol. 2009 Mar;6(1):1-11.

45. Eberle F et al. Modifications in small interfering RNA that separate immunostimulation from RNA interference. J Immunol. 2008 Mar 1;180(5):3229-37.

46. Eguchi et al. Efficient siRNA Delivery into Primary Cells by Peptide Transduction-dsRNA Binding Domain (PTD-DRBD) Fusion Protein. Nat Biotechnol. 2009 June ; 27(6): 567–571.

47. Ehlert E al. Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. BMC Neurosci. 2010 Feb 18;11:20.

48. El Andaloussi S et al. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res. 2011 May 1;39(9):3972-3987. Epub 2011 Jan 17.

49. Elmén J et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008 Mar;36(4):1153-62. Epub 2007 Dec 23.

50. Elmén J et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008 Apr 17;452(7189):896-9. Epub 2008 Mar 26.

51. Ely A et al. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. Nucleic Acids Res. 2009 Jul;37(13):e91.

52. Ely A et al. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and invivo. Mol Ther. 2008 Jun;16(6):1105-12.

53. Epanchintsev A et al. Inducible microRNA expression by all-in-one episomal vector system. Nucleic Acids Res. 2006;34(18):e119.

54. Fedorov Y, King A, Anderson E, Karpilow J, Ilsley D, Marshall W, Khvorova A.Different delivery methods-different expression profiles. Nat Methods. 2005 Apr;2(4):241.

55. Fish RJ et al. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol Biol. 2004 Aug 3;5:9.

56. Fiszer A et al. Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res. 2011 Mar 22.

57. Forsbach A et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol. 2008 Mar 15;180(6):3729-38.

58. Forsbach A, Müller C, Montino C, Kritzler A, Curdt R, Benahmed A, Jurk M, Vollmer J. Impact of delivery systems on siRNA immune activation and RNA interference. Immunol Lett. 2012 Jan 30;141(2):169-80.

59. Frank-Kamenetsky M et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11915-20.

60. Gandellini P et al. Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem Pharmacol. 2007 Jun 1;73(11):1703-14.

61. Gantier MP et al. Nuclear transcription of long hairpin RNA triggers innate immune responses. J Interferon Cytokine Res. 2007 Sep;27(9):789-97.

62. Gantier MP et al. Rational design of immunostimulatory siRNAs. Mol Ther. 2010 Apr;18(4):785-95.

63. Gantier MP et al. TLR7 Is Involved in Sequence-Specific Sensing of Single-Stranded RNAs in Human Macrophages. Nature Medicine. 2008 Feb 15;180(4):2117-24.

64. Ge Q et al. Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA. 2010 Jan;16(1):118-30. Epub 2009 Nov 30.

65. Ge Q et al. Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity. RNA. 2010 Jan;16(1):106-17. Epub 2009 Dec 1.

66. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8676-81.

67. Gebhart CL, Kabanov AV. Evaluation of polyplexes as gene transfer agents. J Control Release. 2001 Jun 15;73(2-3):401-16.

68. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC, Judge A, Jeffs LB,MacLachlan I.Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis. 2006 Jun 15;193(12):1650-7.

69. Gheisari Y et al. Multipotent mesenchymal stromal cells: optimization and comparison of five cationic polymer-based gene delivery methods. Cytotherapy. 2008;10(8):815-23.

70. Ghonaim HM et al. Very long chain N4, N9 -diacyl spermines: non-viral lipopolyamine vectors for efficient plasmid DNA and siRNA delivery. Pharm Res. 2009 Jan;26(1):19-31.

71. Giering JC et al. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther. 2008 Sep;16(9):1630-6.

72. Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia SN, Sharp PA. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):745-50.

73. Gondai T et al. Short-hairpin RNAs synthesized by T7 phage polymerase do not induce interferon. Nucleic Acids Res. 2008 Feb;36(3):e18. Epub 2008 Jan 21.

74. Goodchild A et al. Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol. 2009 Jul 24;10:40.

75. Gorina R et al. Astrocytes are very sensitive to develop innate immune responses to lipid-carried short interfering RNA. Glia. 2009 Jan 1;57(1):93-107.

76. Grayson AC et al. Kinetic and efficacy analysis of RNA interference in stably and transiently expressing cell lines. Mol Pharm. 2006 Sep-Oct;3(5):601-13.

77. Grimm D et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006 May 25;441(7092):537-41.

78. Hamm S et al. Alternating 2'-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology. 2010 Jul;215(7):559-69.

79. Hattori Y, Maitani Y. Low-molecular-weight polyethylenimine enhanced gene transfer by cationic cholesterol-based nanoparticle vector. Biol Pharm Bull. 2007 Sep;30(9):1773-8.

80. Heidel JD et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21.

81. Heidel JD et al. Lack of interferon response in animals to naked siRNAs. Nat Biotechnol. 2004 Dec;22(12):1579-82.

82. Heil F et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004 Mar 5;303(5663):1526-9.

83. Hellgren I et al. Highly efficient cell-mediated gene transfer using non-viral vectors and FuGene6: in vitro and in vivo studies. Cell Mol Life Sci. 2000 Aug;57(8-9):1326-33.

84. Hobel S et al. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med. 2010 Mar;12(3):287-300.

85. Hornung V et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science. 2006 Nov 10;314(5801):994-7. Epub 2006 Oct 12.

86. Hornung V et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005 Mar;11(3):263-70.

87. Huang YH, Bao Y, Peng W, Goldberg M, Love K, Bumcrot DA, Cole G, Langer R, Anderson DG, Sawicki JA. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3426-30.

88. Hutson TH, Foster E, Dawes JM, Hindges R, Yáñez-Muñoz RJ, Moon LD. Lentiviral vectors encoding short hairpin RNAs efficiently transduce and knockdown LINGO-1 but induce an interferon response and cytotoxicity in central nervous system neurones. J Gene Med. 2012 May;14(5):299-315. doi: 10.1002/jgm.2626.

89. Ishimoto T, Takei Y, Yuzawa Y, Hanai K, Nagahara S, Tarumi Y, Matsuo S, Kadomatsu K. Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity. Mol Ther. 2008 Feb;16(2):387-95.

90. Jacobsen LB et al. FuGENE 6 Transfection Reagent: the gentle power. Methods. 2004 Jun;33(2):104-12. 77.

91. Judge AD et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest. 2009 Mar;119(3):661-73.

92. Judge AD et al. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther. 2006 Mar;13(3):494-505.

93. Judge AD et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005 Apr;23(4):457-62. Epub 2005 Mar 20.

94. Kaiser S, Toborek M. Liposome-mediated high-efficiency transfection of human endothelial cells. J Vasc Res. 2001 Mar-Apr;38(2):133-43.

95. Kariko K et al. Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3. Cells Tissues Organs. 2004;177(3):132-8.

96. Kariko K et al. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol. 2004 Jun 1;172(11):6545-9.

97. Kenworthy R et al. Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation. Nucleic Acids Res. 2009 Oct;37(19):6587-99.

98. Khairuddin N et al. siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol. 2011 Mar 22.

99. Khoury M, Escriou V, Courties G, Galy A, Yao R, Largeau C, Scherman D, Jorgensen C, Apparailly F. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum. 2008 Aug;58(8):2356-67.

100. Khoury M, Louis-Plence P, Escriou V, Noel D, Largeau C, Cantos C, Scherman D, Jorgensen C, Apparailly F. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum. 2006 Jun;54(6):1867-77.

101. Kim DH et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol. 2004 Mar;22(3):321-5.

102. Kim DH et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol. 2005 Feb;23(2):222-6.

103. Kim H et al. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int J Pharm. 2010 Jun 15;392(1-2):141-7.

104. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S, Itaya M, Pan Y, Appukuttan B, Gibbs D, Yang Z,Karikó K, Ambati BK, Wilgus TA, DiPietro LA, Sakurai E, Zhang K, Smith JR, Taylor EW, Ambati J. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008 Apr 3;452(7187):591-7.

105. Kodym R et al. 2'-5'-Oligoadenylate synthetase is activated by a specific RNA sequence motif. Biochem Biophys Res Commun. 2009 Oct 16;388(2):317-22.

106. Kodym R et al. 2'-5'-Oligoadenylate synthetase is activated by a specific RNA sequence motif. Biochem Biophys Res Commun. 2009 Oct 16;388(2):317-22.

107. Koo H et al. Analysis of the Relationship between the Molecular Weight and Transfection Efficiency/Cytotoxicity of Poly-L-arginine on a Mammalian Cell Line. Bull. Korean Chem. Soc. 2009, Vol. 30, No. 4.

108. Kornek M et al. 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-formulated, immune-stimulatory vascular endothelial growth factor a small interfering RNA (siRNA) increases antitumoral efficacy in murine orthotopic hepatocellular carcinoma with liver fibrosis. Mol Med. 2008 Jul-Aug;14(7-8):365-73.

109. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, Lee H, Scuto A, Liu Y, Yang C, Deng J, Soifer HS, Raubitschek A, Forman S, Rossi JJ, Pardoll DM, Jove R, Yu H. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol. 2009 Oct;27(10):925-32.

110. Kotnik K et al. Inducible transgenic rat model for diabetes mellitus based on shRNA-mediated gene knockdown. PLoS One. 2009;4(4):e5124. Epub 2009 Apr 2.

111. Krutzfeldt J et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005 Dec 1;438(7068):685-9.

112. Kumar S et al. Intracranial administration of P gene siRNA protects mice from lethal Chandipura virus encephalitis. PLoS One. 2010 Jan 7;5(1):e8615.

113. Lapierre J, Salomon W, Cardia J, Bulock K, Lam JT, Stanney WJ, Ford G, Smith-Anzures B, Woolf T, Kamens J, Khvorova A, Samarsky D. Potent and systematic RNAi mediated silencing with single oligonucleotide compounds. RNA. 2011 Jun;17(6):1032-7.

114. Lee MJ et al. Intraperitoneal gene delivery mediated by a novel cationic liposome in a peritoneal disseminated ovarian cancer model. Gene Ther. 2002 Jul;9(13):859-66.

115. Lee SH et al. Dual gene targeted multimeric siRNA for combinatorial gene silencing. Biomaterials. 2011 Mar;32(9):2359-68.

116. Lee YH, Judge AD, Seo D, Kitade M, Gómez-Quiroz LE, Ishikawa T, Andersen JB, Kim BK, Marquardt JU, Raggi C, Avital I, Conner EA, MacLachlan I, Factor VM,Thorgeirsson SS. Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene. 2011 Oct 6;30(40):4175-84. doi: 10.1038/onc.2011.126.

117. Li Z, Fortin Y, Shen SH.Forward and robust selection of the most potent and noncellular toxic siRNAs from RNAi libraries. Nucleic Acids Res. 2009 Jan;37(1):e8.

118. Li BJ et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med. 2005 Sep;11(9):944-51. Epub 2005 Aug 21.

119. Li SD et al. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther. 2008 May;16(5):942-6.

120. Li ZY et al. The effects of thiophosphate substitutions on native siRNA gene silencing. Biochem Biophys Res Commun. 2005 Apr 15;329(3):1026-30.

121. Liou JY et al. An efficient transfection method for mouse embryonic stem cells. Methods Mol Biol. 2010;650:145-53.

122. Liu C et al. Transient transfection factors for high-level recombinant protein production in suspension cultured mammalian cells. Mol Biotechnol. 2008 Jun;39(2):141-53.

123. Liu J et al. Stable transgene expression in human embryonic stem cells after simple chemical transfection. Mol Reprod Dev. 2009 Jun;76(6):580-6.

124. Liu YP et al. Combinatorial RNAi Against HIV-1 Using Extended Short Hairpin RNAs. Mol Ther. 2009 Oct;17(10):1712-23.

125. Ma Z et al. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun. 2005 May 13;330(3):755-9.

126. Martino S et al. Efficient siRNA delivery by the cationic liposome DOTAP in human hematopoietic stem cells differentiating into dendritic cells. J Biomed Biotechnol. 2009:410260.

127. Masotti A et al. Comparison of different commercially available cationic liposome-DNA lipoplexes: Parameters influencing toxicity and transfection efficiency. Colloids Surf B Biointerfaces. 2009 Feb 1;68(2):136-44.

128. McAllister CS et al. The RNA-activated protein kinase enhances the induction of interferon-beta and apoptosis mediated by cytoplasmic RNA sensors. J Biol Chem. 2009 Jan 16;284(3):1644-51. Epub 2008 Nov 20.

129. McBride JL et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5868-73.

130. McCarroll J et al. Nanotubes functionalized with lipids and natural amino acid dendrimers: a new strategy to create nanomaterials for delivering systemic RNAi. Bioconjug Chem. 2010 Jan;21(1):56-63.

131. Merkel OM et al. Polymer-related off-target effects in non-viral siRNA delivery. Biomaterials. 2011 Mar;32(9):2388-98. Epub 2010 Dec 22.

132. Merkerova M et al. Targeting of gene expression by siRNA in CML primary cells. Mol Biol Rep. 2007 Mar;34(1):27-33.

133. Mook OR et al. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther. 2007 Mar;6(3):833-43.

134. Mook O, Vreijling J, Wengel SL, Wengel J, Zhou C, Chattopadhyaya J, Baas F, Fluiter K.In vivo efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts. Artif DNA PNA XNA. 2010 Jul;1(1):36-44.

135. Mori T et al. Development of a novel nonviral gene silencing system that is effective both in vitro and in vivo by using a star-shaped block copolymer (star vector). Bioconjug Chem. 2009 Jun;20(6):1262-9.

136. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C,Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005 Aug;23(8):1002-7. Epub 2005 Jul 24.

137. Nabzdyk CS et al. High throughput RNAi assay optimization using adherent cell cytometry. J Transl Med. 2011 Apr 25;9:48.

138. Neff CP, Zhou J, Remling L, Kuruvilla J, Zhang J, Li H, Smith DD, Swiderski P, Rossi JJ, Akkina R. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med. 2011 Jan 19;3(66):66ra6.

139. Nguyen DN et al. Drug Delivery–mediated Control of RNA Immunostimulation. Mol Ther. 2009 Sep;17(9):1555-62.

140. Nishina K, Unno T, Uno Y, Kubodera T, Kanouchi T, Mizusawa H, Yokota T. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther. 2008 Apr;16(4):734-40.

141. Nolte A et al. Optimized basic conditions are essential for successful siRNA transfection into primary endothelial cells. Oligonucleotides. 2009 Jun;19(2):141-50.

142. Omidi Y et al. Microarray analysis of the toxicogenomics and the genotoxic potential of a cationic lipid-based gene delivery nanosystem in human alveolar epithelial a549 cells. Toxicol Mech Methods. 2008;18(4):369-78.

143. Omidi Y et al. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J Drug Target. 2003 Jul;11(6):311-23.

144. Orth P et al. Analysis of novel nonviral gene transfer systems for gene delivery to cells of the musculoskeletal system. Mol Biotechnol. 2008 Feb;38(2):137-44.

145. Palliser D et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 2006 Jan 5;439(7072):89-94. Epub 2005 Nov 23.

146. Pauls E et al. Induction of interleukins IL-6 and IL-8 by siRNA. Clin Exp Immunol. 2007 Jan;147(1):189-96.

147. Pebernard S et al. Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 2004 Mar;72(2-3):103-11

148. Perl M et al. Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. Am J Pathol. 2005 Dec;167(6):1545-59.

149. Persengiev SP et al. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA. 2004 Jan;10(1):12-8.

150. Poeck H et al. 5'-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med. 2008 Nov;14(11):1256-63.

151. Pongratz C et al. Selection of potent non-toxic inhibitory sequences from a randomized HIV-1 specific lentiviral short hairpin RNA library. PLoS One. 2010 Oct 8;5(10):e13172.

152. Puthenveetil S et al. Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucleic Acids Res. 2006;34(17):4900-11.

153. Read ML et al. Profiling RNA interference (RNAi)-mediated toxicity in neural cultures for effective short interfering RNA design. J Gene Med. 2009 Jun;11(6):523-34.

154. Reynolds A et al. Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA. 2006 Jun;12(6):988-93. Epub 2006 Apr 12.

155. Robbins et al. Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol. 2006 May;24(5):566-71. Epub 2006 Apr 30.

156. Robbins M et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther. 2008 Oct;19(10):991-9.

157. Robbins Met al. 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther. 2007 Sep;15(9):1663-9. Epub 2007 Jun 19.

158. Sanjoh M et al. pDNA/poly(L-lysine) Polyplexes Functionalized with a pH-Sensitive Charge-Conversional Poly(aspartamide) Derivative for Controlled Gene Delivery to Human Umbilical Vein Endothelial Cells. Macromol Rapid Commun. 2010 Jul 1;31(13):1181-6.

159. Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, Takimoto R, Takada K, Miyanishi K, Matsunaga T, Takayama T, Niitsu Y. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008 Apr;26(4):431-42.

160. Schäfer J et al. Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials. 2010 Sep;31(26):6892-900.

161. Schlee M et al. Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity. 2009 Jul 17;31(1):25-34. Epub 2009 Jul 2.

162. Schmidt A et al. 5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12067-72.

163. Semizarov D et al. Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6347-52. Epub 2003 May 13.

164. Shin D et al. Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs. Biochem Biophys Res Commun. 2007 Dec 21;364(3):436-42.

165. Simberg D et al. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst. 2004;21(4):257-317.

166. Sioud M, Mobergslien A. Efficient siRNA Targeted Delivery into Cancer Cells by Gastrin-Releasing Peptides. Bioconjug Chem. 2012 Apr 10.

167. Sioud M, Sørensen DR. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun. 2003 Dec 26;312(4):1220-5.

168. Sioud M et al. Suppression of immunostimulatory siRNA-driven innate immune activation by 2'-modified RNAs. Biochem Biophys Res Commun. 2007 Sep 14;361(1):122-6.

169. Sioud M. Induction of Inflammatory Cytokines and Interferon Responses by Double-stranded and Single-stranded siRNAs is Sequence-dependent and Requires Endosomal Localization. J Mol Biol. 2005 May 20;348(5):1079-90.

170. Sioud M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2'-hydroxyl uridines in immune responses. Eur J Immunol. 2006 May;36(5):1222-30.

171. Sledz CA et al. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol. 2003 Sep;5(9):834-9.

172. Song E et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biot. 2005 Jun;23(6):709-17.

173. Spagnou S et al. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry. 2004 Oct 26;43(42):13348-56.

174. Stein P et al. Absence of non-specific effects of RNA interference triggered by long double-stranded RNA in mouse oocytes. Dev Biol. 2005 Oct 15;286(2):464-71. Epub 2005 Sep 9.

175. Stewart CK et al. Adverse effects induced by short hairpin RNA expression in porcine fetal fibroblasts. Biochem Biophys Res Commun. 2008 May 23;370(1):113-7. Epub 2008 Mar 20.

176. Stewart CR, Karpala AJ, Lowther S, Lowenthal JW, Bean AG. Immunostimulatory motifs enhance antiviral siRNAs targeting highly pathogenic avian influenza H5N1. PLoS One. 2011;6(7):e21552.

177. Strapps WR, Pickering V, Muiru GT, Rice J, Orsborn S, Polisky BA, Sachs A, Bartz SR. The siRNA sequence and guide strand overhangs are determinants of in vivo duration of silencing. Nucleic Acids Res. 2010 Aug;38(14):4788-97.

178. Su J et al. Silencing microRNA by interfering nanoparticles in mice. Nucleic Acids Res. 2011 Jan 6.

179. Tagami T et al. Global gene expression profiling in cultured cells is strongly influenced by treatment with siRNA-cationic liposome complexes. Pharm Res. 2008 Nov;25(11):2497-504.

180. Tesniere A, Abermil N, Schlemmer F, Casares N, Kepp O, Pequignot M, Michaud M, Martins I, Senovilla L, Zitvogel L,Kroemer G. In vivo depletion of T lymphocyte-specific transcription factors by RNA interference. Cell Cycle. 2010 Jul 15;9(14):2830-5.

181. Terasawa K, Shimizu K, Tsujimoto G.Synthetic Pre-miRNA-Based shRNA as Potent RNAi Triggers. J Nucleic Acids. 2011;2011:131579.

182. Tluk S et al. Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses. Int Immunol. 2009 May;21(5):607-19.

183. Tompkins SM et al. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8682-6.

184. Tschuch C et al. Off-target effects of siRNA specific for GFP. BMC Mol Biol. 2008 Jun 24;9:60.

185. Uchida E et al. Comparison of the efficiency and safety of non-viral vector-mediated gene transfer into a wide range of human cells. Biol Pharm Bull. 2002 Jul;25(7):891-7.

186. Van Vliet LD et al. Relating chemical and biological diversity space: a tunable system for efficient gene transfection. Chembiochem. 2008 Aug 11;9(12):1960-7.

187. Vitali P, Scadden AD. Double-stranded RNAs containing multiple IU pairs are sufficient to suppress interferon induction and apoptosis. Nat Struct Mol Biol. 2010 Sep;17(9):1043-50.

188. Wang H et al. Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. J Biol Chem. 2008 Jun 6;283(23):15845-52.

189. Wesche-Soldato et al. In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood. 2005 Oct 1;106(7):2295-301.

190. Witting SR et al. Helper-dependent adenovirus-mediated short hairpin RNA expression in the liver activates the interferon response. J Biol Chem. 2008 Jan 25;283(4):2120-8. Epub 2007 Nov 19.

191. Wong AW et al. DNA internalized via caveolae requires microtubule-dependent, Rab7-independent transport to the late endocytic pathway for delivery to the nucleus. J Biol Chem. 2007 Aug 3;282(31):22953-63.

192. Wu Y et al. Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe. 2009 Jan 22;5(1):84-94.

193. Yalvac ME et al. Comparison and optimisation of transfection of human dental follicle cells, a novel source of stem cells, with different chemical methods and electro-poration. Neurochem Res. 2009 Jul;34(7):1272-7.

194. Yang XZ, Dou S, Sun TM, Mao CQ, Wang HX, Wang J.Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. J Control Release. 2011 Dec 10;156(2):203-11.

195. Ye X, Liu Z, Hemida MG, Yang D.Targeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNA. PLoS One. 2011;6(6):e21215.

196. Yokota T e al. Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C. Biochem Biophys Res Commun. 2007 Sep 21;361(2):294-300.

197. Yoo JW et al. Inflammatory cytokine induction by siRNAs is cell type- and transfection reagent-specific. Biochem Biophys Res Commun. 2006 Sep 8;347(4):1053-8.

198. Yueksekdag G, Drechsel M, Rössner M, Schmidt C, Kormann M, Illenyi MC, Rudolph C, Rosenecker J. Repeated siRNA application is a precondition for successful mRNA gammaENaC knockdown in the murine airways. Eur J Pharm Biopharm. 2010 Aug;75(3):305-10.

199. Zamanian-Daryoush M et al. Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. J Interferon Cytokine Res. 2008 Apr;28(4):221-33.

200. Zamora MR, Budev M, Rolfe M, Gottlieb J, Humar A, Devincenzo J, Vaishnaw A, Cehelsky J, Albert G, Nochur S, Gollob JA, Glanville AR. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2011 Feb 15;183(4):531-8.

201. Zhang M et al. Downregulation enhanced green fluorescence protein gene expression by RNA interference in mammalian cells. RNA Biol. 2004 May;1(1):74-7.

202. Zhao M et al. Lipofectamine RNAiMAX: an efficient siRNA transfection reagent in human embryonic stem cells. Mol Biotechnol. 2008 Sep;40(1):19-2.

203. Zimmermann TS et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006 May 4;441(7089):111-4. Epub 2006 Mar 26.